Stocks · News reference

Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $118

Aug 19, 2026, 5:57 PMBenzinga Newsdesk

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $118.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 21, 2026, 12:24 PMAvi Kapoor
Ross Stores To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed outlook on top names. Baird raised PSN target, BTIG cut WMT target, HSBC raised TX target, Rothschild upgraded EFX, HC Wainwright lowered COCH target, BTIG cut MDXH target, Baird raised ROST target.
Read original at benzinga
COCH DE EFX HAE HTB
BenzingaAug 21, 2026, 12:18 PMBenzinga Newsdesk
Baird Maintains Outperform on Haemonetics, Raises Price Target to $119
Baird analyst David Rescott maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $96 to $119.
Read original at benzinga
HAE
BenzingaAug 18, 2026, 5:12 PMHenry Khederian
Haemonetics Shares Hit New 52-Week High: What's Happening?
Shares of Haemonetics Corp (NYSE: HAE) are trading higher Tuesday afternoon following news of a significant commercial agreement.
Read original at benzinga
HAE